LOG IN
SIGN UP
MARKET
GH
GH
Guardant Health
NASDAQ
Real-time Quotes | Nasdaq Last Sale
43.66
+3.32
+8.23%
After Hours: 43.03 -0.63 -1.44% 16:05 07/01 EDT
OPEN
40.39
PREV CLOSE
40.34
HIGH
43.76
LOW
40.37
VOLUME
833.63K
TURNOVER
0
52 WEEK HIGH
133.82
52 WEEK LOW
27.65
MARKET CAP
4.45B
P/E (TTM)
-10.5755
1D
5D
1M
3M
1Y
5Y
GH, FUV and CBAY among after hour movers.
Gainers:Scholar Rock Holding (SRRK) +6%. Science 37 Holdings (SNCE) +6%. Arcimoto (FUV) +5%. Hyzon Motors (HYZN) +4%. SoundHound (SOUN) +4%. Losers: Guardant Health (GH) -5%. CymaBay Therapeutics (CBAY) -5%. Polestar Automotive
Seekingalpha · 06/24 21:23
Guardant Health Closes Guardant Health AMEA Joint Venture Buyout for $177.8 Million
MT Newswires · 06/13 11:01
Piper Sandler Starts Guardant Health at Overweight With $65 Price Target
MT Newswires · 06/03 05:36
Guardant Health to Participate in Upcoming June Investor Conferences
REDWOOD CITY, Calif., May 26, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
Business Wire · 05/26 20:05
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
PALO ALTO, Calif. & BARCELONA, Spain, May 25, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, today announced that th...
Business Wire · 05/25 07:01
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
PALO ALTO, Calif., May 23, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Among the ...
Business Wire · 05/23 12:05
BRIEF-Guardant Health Presents New Data Showing Blood Test Accuracy In Detecting Colorectal Cancer In Study At Digestive Disease Week 2022
reuters.com · 05/21 07:04
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
PALO ALTO, Calif., May 21, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced data showing its blood-based multimodal test achieved clinically significant thresholds of sensitivity and specificity in detecting c...
Business Wire · 05/21 07:01
No Data
Learn about the latest financial forecast of GH. Analyze the recent business situations of Guardant Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 15 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
46.67%Strong Buy
40.00%Buy
13.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GH stock price target is 117.73 with a high estimate of 170.00 and a low estimate of 65.00.
Current 43.66
EPS
Actual
Estimate
-0.97-0.73-0.48-0.24
Institutional Holdings
Institutions: 476
Institutional Holdings: 98.94M
% Owned: 97.08%
Shares Outstanding: 101.92M
TypeInstitutionsShares
Increased
104
10.41M
New
47
1.26M
Decreased
133
9.13M
Sold Out
81
1.99M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/Co-Chief Executive Officer/Director
Helmy Eltoukhy
President/Co-Chief Executive Officer/Director
Amirali Talasaz
Chief Financial Officer
Michael Bell
Senior Vice President/General Counsel/Secretary
John Saia
Other
Craig Eagle
Other
Christopher Freeman
Lead Director/Independent Director
Ian Clark
Independent Director
Vijaya Gadde
Independent Director
Meghan Joyce
Independent Director
Samir Kaul
Independent Director
Myrtle Potter
No Data
No Data
About GH
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood-based tests, data sets and advanced analytics. It has developed its Guardant360, Guardant360 CDx and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need in Stage II-III colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor Deoxyribonucleic Acid (DNA) in blood. The Company's tests are used by biopharmaceutical companies for a range of applications, including identifying target patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic development.
Webull offers kinds of Guardant Health Inc stock information, including NASDAQ:GH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GH stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading GH stock methods without spending real money on the virtual paper trading platform.